Skip to main content
    E

    Edwards Lifesciences Corp (EW)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NYSE

    $107.11
    -0.04 (-0.04%)

    Market Cap: $61.61B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Edwards Lifesciences Corp (EW) Financials: Revenue, Profit and Cash Flow

    Updated Nov 4, 2026. Financial statements from company filings, amounts in US dollars.

    Edwards Lifesciences reported revenue of $6.07B for the fiscal year ended Dec 31, 2025, up 11.5% from the year before. That year, net income was $1.07B with a net margin of 17.6%, operating cash flow was $1.60B and free cash flow was $1.33B. The quarter ended Sep 30, 2026 had revenue of $1.72B and net income of $301.40M.

    Revenue and Margins

    The operating margin was 20.8% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $2.96B, a compound annual rate of 8.3%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$6.07B+11.5%78.0%20.8%17.6%
    Dec 2024$5.44B+8.6%79.5%25.3%76.7%
    Dec 2023$5.01B+12.2%80.5%26.1%27.9%
    Dec 2022$4.46B-14.7%83.8%33.6%34.1%
    Dec 2021$5.23B+19.3%76.1%32.3%28.7%
    Dec 2020$4.39B+0.9%75.4%20.5%18.8%
    Dec 2019$4.35B+16.8%74.4%26.4%24.1%
    Dec 2018$3.72B+8.4%74.8%20.1%19.4%
    Dec 2017$3.44B+15.9%74.5%31.7%17.0%
    Dec 2016$2.96BN/A73.1%25.3%19.2%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, net income fell 74.3% from the year before. In the quarter ended Sep 2026, net income rose 3.8% from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$6.07B$5.44B$5.01B$4.46B$5.23B$4.39B$4.35B$3.72B$3.44B$2.96B
    Cost of revenue$1.33B$1.12B$978.40M$723.70M$1.25B$1.08B$1.11B$939.40M$875.30M$797.40M
    Gross profit$4.73B$4.32B$4.03B$3.74B$3.98B$3.31B$3.23B$2.78B$2.56B$2.17B
    Research and development$1.08B$1.05B$962.90M$843.60M$903.10M$760.70M$752.70M$622.20M$552.60M$442.20M
    Operating income$1.26B$1.38B$1.31B$1.50B$1.69B$897.60M$1.15B$748.20M$1.09B$751.20M
    Net income$1.07B$4.17B$1.40B$1.52B$1.50B$823.40M$1.05B$722.20M$583.60M$569.50M
    EBITDA$1.28B$1.60B$1.47B$1.64B$1.84B$1.02B$1.27B$836.70M$1.12B$817.50M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$1.72B$1.74B$1.65B$1.57B$1.55B$1.53B$1.41B$1.39B$1.35B$1.37B$1.33B$1.01B
    Gross profit$1.35B$1.35B$1.29B$1.23B$1.21B$1.19B$1.11B$1.09B$1.09B$1.09B$1.04B$870.10M
    Operating income$299.10M$513.20M$477.60M$151.10M$307.10M$411.20M$394.80M$312.60M$350.60M$366.50M$349.00M$291.10M
    Net income$301.40M$241.40M$380.70M$91.20M$290.30M$331.50M$356.40M$384.30M$3.07B$365.00M$351.00M$369.70M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded total debt of $622.80M by $2.32B.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$13.70B$13.06B$9.36B$8.29B$8.50B$7.24B$6.49B$5.32B$5.67B$4.51B
    Current assets$6.74B$6.29B$4.04B$3.10B$3.18B$3.09B$2.98B$2.29B$2.55B$2.24B
    Cash and equivalents$2.94B$3.05B$1.13B$769.00M$862.80M$1.18B$1.18B$714.10M$818.30M$930.10M
    Total liabilities$3.36B$2.99B$2.64B$2.49B$2.67B$2.66B$2.34B$2.18B$2.71B$1.89B
    Short-term debt$24.50M$23.40M$22.90M$25.50M$25.50M$27.20M$25.50M$0$649.70M$0
    Long-term debt$598.30M$597.70M$597.00M$596.30M$595.70M$595.00M$594.40M$593.80M$438.40M$822.30M
    Shareholder equity$10.34B$10.00B$6.65B$5.81B$5.84B$4.57B$4.15B$3.14B$2.96B$2.62B
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$14.14B$13.87B$13.32B$13.70B$13.27B$13.49B$13.02B$13.06B$12.97B$10.10B$9.74B$9.36B
    Total liabilities$3.18B$3.14B$2.99B$3.36B$3.07B$2.88B$2.83B$2.99B$3.36B$2.59B$2.55B$2.64B
    Cash and equivalents$3.11B$2.91B$2.45B$2.94B$2.69B$3.27B$3.14B$3.05B$3.68B$1.64B$1.22B$1.13B
    Shareholder equity$10.86B$10.62B$10.33B$10.34B$10.21B$10.55B$10.13B$10.00B$9.55B$7.44B$7.12B$6.65B
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 83.1% of operating cash flow. Share repurchases came to 67.2% of it.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow$1.60B$542.30M$895.80M$1.22B$1.73B$1.05B$1.18B$926.70M$1.00B$704.40M
    Capital expenditures$260.20M$252.40M$253.00M$244.60M$325.80M$407.00M$254.40M$238.70M$168.10M$176.10M
    Free cash flow$1.33B$289.90M$642.80M$973.60M$1.41B$647.30M$928.50M$688.00M$832.60M$528.30M
    Dividends paidN/AN/A$169.90M$146.40M$158.60M$140.50M$18.90M$688.00M$0$253.50M
    Share repurchases$893.40M$1.16B$879.60M$1.73B$512.80M$625.40M$263.30M$795.50M$763.30M$662.30M
    Investing cash flow-$712.90M$2.31B$173.80M$252.30M-$1.72B-$531.10M-$595.80M$76.70M-$647.20M-$211.70M
    Financing cash flow-$956.80M-$983.00M-$711.00M-$1.58B-$356.30M-$486.90M-$115.60M-$1.10B-$473.20M-$268.50M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow$570.30M$651.90M$43.80M$450.90M$573.70M$290.20M$280.40M-$127.50M$351.80M$371.50M-$53.50M$136.60M
    Capital expenditures$63.60M$66.90M$64.90M$97.40M$57.50M$49.30M$56.00M$49.80M$51.90M$85.40M$65.30M$88.30M
    Free cash flow$506.70M$585.00M-$21.10M$353.50M$516.20M$240.90M$224.40M-$177.30M$299.90M$286.10M-$118.80M$48.30M
    Last 12 quarters

    Frequently Asked Questions About EW

    What is Edwards Lifesciences' annual revenue?

    Edwards Lifesciences reported revenue of $6.07B for the fiscal year ended Dec 31, 2025.

    How fast is Edwards Lifesciences' revenue growing?

    Revenue was up 11.5% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 10.8%.

    Is Edwards Lifesciences profitable?

    Yes. Edwards Lifesciences reported net income of $1.07B for the fiscal year ended Dec 31, 2025, with a net margin of 17.6%.

    How much free cash flow does EW generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $1.60B minus capital expenditures of $260.20M produced free cash flow of $1.33B.

    How much debt does Edwards Lifesciences have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $598.30M, short-term debt of $24.50M and cash and equivalents of $2.94B.